1. Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity
- Author
-
Tiedemann, Rodger E., Mao, Xinliang, Shi, Chang-Xin, Zhu, Yuan Xiao, Palmer, Stephen E., Sebag, Michael, Marler, Ron, Chesi, Marta, Fonseca, Rafael, Bergsagel, P. Leif, Schimmer, Aaron D., and Stewart, A. Keith
- Subjects
Gene expression -- Health aspects ,Gene expression -- Methods ,Gene expression -- Research ,Multiple myeloma -- Risk factors ,Multiple myeloma -- Diagnosis ,Multiple myeloma -- Genetic aspects ,Multiple myeloma -- Research ,Plant hormones -- Health aspects ,Plant hormones -- Genetic aspects ,Plant hormones -- Research - Abstract
Knockout and transgenic studies in mice demonstrate that normal somatic tissues redundantly express 3 cyclin D proteins, whereas tumor cells seem dependent on a single overexpressed cyclin D. Thus, selective suppression of the individual cyclin D deregulated in a tumor represents a biologically valid approach to targeted cancer therapy. In multiple myeloma, overexpression of 1 of the cyclin D proteins is a ubiquitous feature, unifying at least 7 different initiating genetic events. We demonstrate here that RNAi of genes encoding cyclin D1 and cyclin D2 (CCND1 and CCND2, respectively) inhibits proliferation and is progressively cytotoxic in human myeloma cells. By screening a chemical library using a cell-based assay for inhibition of CCND2 trans-activation, we identified the plant cytokinin kinetin riboside as an inhibitor of CCND2 trans-activation. Kinetin riboside induced marked suppression of CCND2 transcription and rapidly suppressed cyclin D1 and D2 protein expression in primary myeloma cells and tumor lines, causing cell-cycle arrest, tumor cell--selective apoptosis, and inhibition of myeloma growth in xenografted mice. Mechanistically, kinetin riboside upregulated expression of transcription repressor isoforms of cAMP-response element modulator (CREM) and blocked both trans-activation of CCND2 by various myeloma oncogenes and cis-activation of translocated CCND1, suggesting induction of an overriding repressor activity that blocks multiple oncogenic pathways targeting cyclin D genes. These data support targeted repression of cyclin D genes as a therapeutic strategy for human malignancies., Introduction Multiple myeloma (MM) is a postgerminal center B cell malignancy characterized by clonal plasma cell expansion. The disease manifests clinically with anemia, monoclonal immunoglobulin, renal insufficiency, and lytic bone [...]
- Published
- 2008